Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial

Vitiligo development in melanoma patients during immunotherapy is a favorable prognostic sign and indicates breakage of tolerance against melanocytic/melanoma antigens. We investigated a novel immunotherapeutic approach of the skin-depigmenting compound monobenzone synergizing with imiquimod in indu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Teulings, Hansje-Eva, Tjin, Esther P. M., Willemsen, Karina J., van der Kleij, Stephanie, ter Meulen, Sylvia, Kemp, E. Helen, Krebbers, Gabrielle, van Noesel, Carel J. M., Franken, Cornelis L. M. C., Drijfhout, Jan W., Melief, Cornelis J. M., Nieuweboer-Krobotova, Ludmila, Nieweg, Omgo E., van der Hage, Jos A., van der Veen, J. P. Wietze, Relyveld, Germaine N., Luiten, Rosalie M.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889200/
https://ncbi.nlm.nih.gov/pubmed/29632737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1419113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars